近日，康德（深圳）生物技术股份有限公司（下称“康德生物”）核心产品逸力嘉®胰腺癌早期精准检测试剂盒（以下简称“逸力嘉®”）正式获得香港卫生署医疗仪器科（Medical Device Division Department of Health，简称“香港MDD”）注册批准。此次MDD注册的顺利获批，标志着逸力嘉®已具备进入中国香港市场的合规资质，更成为康德生物推进全球化战略布局，打造亚洲癌症防治范本 ...

Can New Devices be Approved from Single Arm Studies: Use of Real-World Data as an External Control Group or for Propensity Matching or Generating Objective Performance Criteria Receive the the latest ...

It is a leading cause of disability on a global scale, adversely affecting physical health, interpersonal relationships, and much more for those affected. tDCS devices offer an innovative solution for ...

The Medical Device Classification webinar explains the classification system in the US, the EU, following the Medial Device Directive (MDD), and the Canadian Medical Device Regulations (CMDR), and the ...